Cambridge enters vaccine race with £1.9m grant support
CAMBRIDGE University aims to start clinical trials of its coronavirus vaccine in the autumn after getting a £1.9m government grant.
The scientists behind the vaccine say their approach, which uses genetic sequences of all known coronaviruses to hone the immune response, could help to avoid the adverse effects of a hyperinflammatory response.
“We’re looking for chinks in its armour, crucial pieces of the virus that we can use to construct the vaccine to direct the immune response in the right direction,” said Jonathan Heeney, head of Cambridge’s laboratory of viral zoonotics. “Ultimately, we aim to make a vaccine that will not only protect from SARS-CoV-2, but also other related coronaviruses that may spill over from animals to humans.”
No vaccine against the SARS-CoV-2 coronavirus which causes Covid-19 has yet been proven clinically effective, although 30 that use a range of technologies are currently in human trials.
The Cambridge candidate, DIOS-CoVax2, is DNA-based.